CAR T cells have been very successful therapies for people with blood cancers who have not responded to other treatments. But now the FDA is concerned that the cellular therapy might be linked to the ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

In a large US cohort study, patients with primary cutaneous B-cell lymphoma (pCBCL) had significantly higher risks of developing hematologic and prostate cancers. Researchers analyzed data from 3757 ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...